tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
PremiumRatingsBeam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
8d ago
Beam Therapeutics price target raised to $47 from $45 at BofA
Premium
The Fly
Beam Therapeutics price target raised to $47 from $45 at BofA
8d ago
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
Premium
The Fly
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
9d ago
Beam Therapeutics initiated with a Buy at Canaccord
PremiumThe FlyBeam Therapeutics initiated with a Buy at Canaccord
13d ago
Beam Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Beam Therapeutics initiated with a Buy at Canaccord
13d ago
Cathie Wood Loads Up on Momentum Stocks after Earnings Rally. Should You Follow?
Premium
Market News
Cathie Wood Loads Up on Momentum Stocks after Earnings Rally. Should You Follow?
17d ago
Cathie Wood Dumps Over $5M in a Biotech Stock, Buys WeRide and Tempus AI
PremiumMarket NewsCathie Wood Dumps Over $5M in a Biotech Stock, Buys WeRide and Tempus AI
1M ago
Beam Therapeutics: Buy Rating Backed by BEAM-302 Progress, 2026 Data Catalyst, and De-Risked Accelerated Approval Path
Premium
Ratings
Beam Therapeutics: Buy Rating Backed by BEAM-302 Progress, 2026 Data Catalyst, and De-Risked Accelerated Approval Path
1M ago
Cathie Wood Buys Netflix and AI Stocks, Dumps Beam, PINS, and GitLab Shares
Premium
Market News
Cathie Wood Buys Netflix and AI Stocks, Dumps Beam, PINS, and GitLab Shares
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100